Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.

Shinichi Sato1, Manabu Fujimoto, Minoru Hasegawa

  • 1Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. s-sato@med.kanazawa-u.ac.jp

Molecular Immunology
|October 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Nature communications·2026
Same author

Perspective to precision medicine in scleroderma.

Frontiers in immunology·2024
Same author

GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Nature communications·2024
Same author

Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.

Modern rheumatology·2023
Same author

Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.

Journal of scleroderma and related disorders·2022
Same author

A role for FcγRIIB in the development of murine bleomycin-induced fibrosis.

Journal of dermatological science·2021

Systemic sclerosis involves B cell abnormalities, particularly CD19 overexpression, leading to autoantibodies and skin fibrosis. Targeting CD19 signaling may treat this autoimmune disease.

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Systemic sclerosis (SSc) is a connective tissue disease marked by excessive extracellular matrix deposition and immune activation.
  • Autoantibodies and B cell dysfunction are central to SSc pathogenesis, but their direct link to clinical manifestations like skin fibrosis is unclear.
  • B cells are crucial in autoimmunity, producing cytokines and autoantibodies, with their signaling thresholds regulated by molecules like CD19.

Purpose of the Study:

  • To investigate the role of CD19, a key B cell regulator, in SSc pathogenesis.
  • To determine if increased CD19 expression in SSc patients' B cells contributes to autoantibody production and fibrosis.
  • To explore CD19 signaling as a therapeutic target for SSc.

Main Methods:

Related Experiment Videos

  • Analysis of CD19 expression on B cells from SSc patients and a tight-skin mouse model.
  • Utilizing transgenic mice to assess the impact of CD19 overexpression on autoantibody production.
  • Investigating the effects of CD19 modulation on B cell hyper-reactivity, IL-6 production, and skin fibrosis in mice.

    • Main Results:

    • SSc patients' B cells show a 20% increase in CD19 expression, inducing SSc-specific autoantibodies in transgenic mice.
    • SSc patients exhibit intrinsic B cell abnormalities, including chronic hyper-reactivity potentially due to CD19 overexpression.
    • CD19 loss inhibited B cell hyper-reactivity and autoantibody production, improving skin fibrosis and reducing IL-6 in tight-skin mice.

    Conclusions:

    • Augmented CD19 signaling in B cells drives chronic B cell activation, leading to autoantibody production and skin fibrosis in SSc.
    • CD19 overexpression is a key factor in SSc pathogenesis, linking B cell hyperactivity to disease manifestations.
    • Targeting CD19 signaling presents a potential therapeutic strategy for managing systemic sclerosis.